Skip to main content
Clinical Trials/NCT06703125
NCT06703125
Recruiting
Not Applicable

The Alama Project: Autism Outcomes and Neurobehavioral Markers in Young Children Born to Mothers With HIV in Kenya

Indiana University1 site in 1 country850 target enrollmentFebruary 11, 2025
ConditionsAutism

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autism
Sponsor
Indiana University
Enrollment
850
Locations
1
Primary Endpoint
Agreement between eye-tracking biomarker score and autism diagnosis
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures to determine whether these can predict autism diagnoses in both children exposed to HIV and uninfected (CHEU) and children not exposed to HIV and uninfected (CHUU).

Detailed Description

The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series (less than 15 mins) of eye-tracking measures (e.g., looking time, pupil diameter, oculomotor dynamics), which may be associated with autism outcomes. Investigators will recruit children enrolled in the Tabiri study during or following their 24-month visit. The Tabiri study is comparing neurodevelopmental (ND) outcomes between 24-month-old CHEU and CHUU.

Registry
clinicaltrials.gov
Start Date
February 11, 2025
End Date
February 28, 2029
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rebecca McNally Keehn

Assistant Professor of Pediatrics

Indiana University

Eligibility Criteria

Inclusion Criteria

  • Children enrolled in the Tabiri study (R01HD104552)
  • CHEU or CHUU
  • Children ages 24-72 months
  • Caregivers of children must speak Kiswahili (local language) or English.

Exclusion Criteria

  • There will be no specific exclusion criteria. We anticipate that a small number of CHEU and CHUU will develop HIV prior to enrollment in the current study; these children will be included and will follow all general study procedures.

Outcomes

Primary Outcomes

Agreement between eye-tracking biomarker score and autism diagnosis

Time Frame: Day 1

The composite eye-tracking biomarker score, a consolidated measure based on eye-tracking indices that predict autism outcome, will be compared to the categorical autism diagnosis (autism presence/absence). Clinical diagnosis is obtained based upon a standard clinical evaluation. The evaluation will include 1) a semi-structured caregiver(s) clinical interview to gather information about developmental history and autism symptoms and 2) a battery of standardized child clinical observational measures. The evaluation will be conducted over a one-time 2- to 3-hour clinical autism evaluation. Eye-tracking will be recorded immediately following the clinical evaluation.

Study Sites (1)

Loading locations...

Similar Trials